Pharmacogenetics of timolol (in Russian only)

Moshetova L.K.; Soshina M.M.; Sychev D.A.; Turkina K.I.

doi:https://doi.org/10.17116/oftalma2019135031137

Close metadata

Recommended articles:

The possibilities of antioxidant neuroretinoprotection in the treatment of primary open-angle glaucoma. Russian Annals of Ophthalmology. 2025;(4):49-59

Electrophysiological methods in the diagnosis and monitoring of glaucoma. Russian Annals of Ophthalmology. 2025;(4):102-109

The effect of initial conservative hypotensive therapy on the outcomes of selective laser trabeculoplasty in primary open-angle glaucoma. Russian Annals of Ophthalmology. 2025;(5):16-22

Modern devices for microinvasive glaucoma surgery. Russian Annals of Ophthalmology. 2025;(5):101-108

Neuroprotective therapy in advanced primary open-angle glaucoma. Russian Annals of Ophthalmology. 2025;(6):75-80

Remodelling of the lamina cribrosa of the sclera in optic nerve axonal injury. Russian Annals of Ophthalmology. 2026;(1):60-69

Trends in glaucoma morbidity in Uzbekistan. Russian Annals of Ophthalmology. 2026;(1):108-111

Effect of polymorphic variants of the HTR2A gene on the effectiveness and safety of sertraline in patients with mixed anxiety-depressive disorder. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):75-84

Associations of polymorphic variants of CYP2C19*2, *17 with effectiveness and safety of sertraline in adolescents with a depressive episode and suicidal tendencies. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):12-20

News in molecular biology. Digest of scientific publications. Issue 2. Laboratory Service. 2025;(4):5-7

Abstract:

In recent years, β-adrenergic blockers have become the first choice drugs for glaucoma treatment. Timolol holds the main position among them, being a part of most combined antiglaucoma preparations. The use of timolol maleate in clinical practice may be accompanied by severe side effects affecting different organs and systems. The fact that cells with β-adrenergic receptors are widely common within the human body explains pharmacodynamic effects of timolol maleate. Because of these undesirable side effects, timolol maleate often evokes negative reaction from doctors and patients, which to certain extent limits its usage in ophthalmological practice. Obviously, efficacy and safety of timolol administration depends on individual characteristics making personalized approach necessary for every patient. Such particular approach, being the foundation of personalized medicine, increases efficacy and safety of timolol while reducing costs by using targeted doses.

Keywords:

glaucoma

timolol maleate

farmacogenetics

cytochrome p450

β-adrenergic blockers

Authors:

Moshetova L.K.

Russian Medical Academy of Postgraduate Education, Ophthalmology Department, Ministry of Health of the Russian Federation, 2/1 Barrikadnaya St., Moscow, Russian Federation, 123242, City Clinical Hospital named after S.P. Botkin, Branch №1, Moscow Health Department, 7 Mamonovskiy pereulok, Moscow, Russian Federation, 123001

Soshina M.M.

Russian Medical Academy of Continuous Professional Education, Department of Ophthalmology, 2/1 Barricadnaya St., Moscow, Russian Federation, 125993

Sychev D.A.

Russian Medical Academy of Continuous Professional Education, Ministry of Health of the Russia, Moscow, Russia

Turkina K.I.

Russian Medical Academy of Postgraduate Education, Ministry of Health of the Russian Federation, 2/1 Barrikadnaya St., Moscow, Russian Federation, 125993

Close metadata

References:

Natsional’noe rukovodstvo po glaukome dlya praktikuyushchikh vrachei. 3-e izd. Pod red. prof. Egorova E.A., prof. Astakhova Yu.S., prof. Ericheva V.P. M.: GEOTAR-Media; 2015. (In Russ.)
Kuroyedov AV, Brezhnev AYu. The duration of the hypotensive action of anti-glaucoma medicines. RMJ. Klinicheskaya oftal’mologiya. 2016;4:214-219. (In Russ.) https://doi.org/10.21689/2311-7729-2016-16-4-214-219
Nesterov AP. Glaukoma. M.: Meditsina; 1995. (In Russ.)
Nouri-Mahdavi K, Hoffman D, Coleman AL, Liu G, Li G, Gaasterland D, Caprioli J. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology. 2004;111(9):1627-1635. https://doi.org/10.1016/j.ophtha.2004.02.017
Oftal’mologiya. Natsional’noe rukovodstvo. Pod red. Avetisova S.E., Egorova E.A., Moshetovoi L.K., Neroeva V.V., Takhchidi Kh.P. M.: GEOTAR-Media; 2013. (In Russ.)
Kuroyedov AV. Prospects of combined antiglaucoma drugs usage (literary review). Klinicheskaya oftal’mologiya. 2007;4:176-180.(In Russ.)
Rukovodstvo po klinicheskoi oftal’mologii. Pod red. Brovkinoi A.F., Astakhova Yu.S. M.: OOO 'Izdatel’stvo 'Meditsinskoe informatsionnoe agentstvo'; 2014. (In Russ.)
Covert D, Robin AL. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Current Medical Research and Opinion. 2006;22(5):971-976. https://doi.org/10.1185/030079906x104777
Egorov EA, Egorov AE. Beta-blokers in treatment of glaucoma. Back to the future. Literature review. RMJ. Klinicheskaya oftal’mologiya. 2013;3:92. (In Russ.)
Grieshaber MC, Flammer J. Is the medication used to achieve the target intraocular pressure in glaucoma therapy of relevance? — An exemplary analysis on the basis of two beta-blockers. Progress in Retinal and Eye Research. 2010;29:79-93. https://doi.org/10.1016/j.preteyeres.2009.08.002
Allen RC, Hertzmark E, Walker AM, Epstein DL. A double — masked comparison of betaxolol vs. timolol in the treatment of open — angle glaucoma. American Journal of Ophthalmology. 1986;101(535):41. https://doi.org/10.1016/0002-9394(86)90942-6
Ghate D, Edelhauser HF. Barriers to glaucoma drug delivery. Journal of Glaucoma. 2008;17:147-156. https://doi.org/10.1097/ijg.0b013e31814b990d
Sakanaka K, Kawazu K, Nishida K, Nakamura J, Nakashima M, Nakamura T, Oshita A, Ichikawa N, Sasaki H. Transport of timolol and tilisolol in rabbit corneal epithelium. Biological & Pharmaceutical Bulletin. 2006;29:2143-2147. https://doi.org/10.1248/bpb.29.2143
Volotinen M, Mäenpää J, Kautiainen H, Tolonen A, Uusitalo J, Ropo A, Vapaatalo H, Aine E. Ophthalmic timolol in a hydrogel vehicle leads to minor inter-individual variation in timolol concentration in aqueous humor. European Journal of Pharmaceutical Sciences. 2009;36:292-296. https://doi.org/10.1016/j.ejps.2008.10.004
Volotinen M, Turpeinen M, Tolonen A, Uusitalo J, Maenpaa J, Pelkonen O. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. Drug Metabolism and Disposition. 2007;35:1135-1141. https://doi.org/10.1124/dmd.106.012906
Zhang T, Xiang CD, Gale D, Carreiro S, Wu EY, Zhang EY. Drug transporter and cytochrome P450 mRNA expression in human ocular barriers: implications for ocular drug disposition. Drug Metabolism and Disposition. 2008;36:1300-1307. https://doi.org/10.1124/dmd.108.021121
Volotinen M, Hakkola J, Pelkonen O, Vapaatalo H, Mäenpää J. Metabolism of ophthalmic timolol: new aspects of an old drug. Basic & Clinical Pharmacology & Toxicology. 2011;108:297-303. https://doi.org/10.1111/j.1742-7843.2011.00694.x
Alvan G, Calissendorf B, Seideman P, Wildmark K, Wildmark G. Absorbtion of ocular timolol. Clinical Pharmocokinetics. 1980;5(1):95-100. https://doi.org/10.2165/00003088-198005010-00004
Korte JM, Kaila T, Saari KM. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2002;240:430-435. https://doi.org/10.1007/s00417-002-0462-2
Goldberg I, Moloney G, McCluskey P. Topical ophthalmic medications: what potential for systemic side effects and interactions with other medications? The Medical Journal of Australia. 2008;189:356-357.
Zimmerman TJ, Kaufman HE. Timolol, a beta-adrenergic blocking agent for the treatment of glaucoma. Archives of Ophthalmology. 1977;95:601-604. https://doi.org/10.1001/archopht.1977.04450040067008
Juha-Matti Korte, Timo K, Matti K Saari. Systemic bioavailability and cardiopulmonary effects of 0.5% timololeyedrops. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2002;240:430-435. https://doi.org/10.1007/s00417-002-0462-2
Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance. Clinical Pharmacokineticks. 2009;48:689-723. https://doi.org/10.2165/11318030-000000000-00000
Woolf TF. Handbook of drug metabolism. New York: Marcel Dekker; 1999.
Brayfield A (ed.). Timolol Maleate. Martindale: Complete Drug Reference. London: Pharmaceutical Press. 2016. Accessed May, 11, 2017.https://www.medicinescomplete.com/mc/excipients/current/search.htm?q=Timolol%20Maleate.%20Martindale%3A%20Complete%20Drug%20Reference
Fourtillan JB, Courtois P, Lefebvre MA, Girault J. Pharmacokinetics of oral timolol studied by mass fragmentography. European Journal of Clinical Pharmacology. 1981;19(3):193-196. https://doi.org/10.1007/bf00561948
Kukes VG, Grachev SV, Sychev DA, Ramenskaya GV. Metabolizm lekarstvennykh sredstv: nauchnye osnovy personalizirovannoi meditsiny. M.: GEOTAR-Media; 2008. (In Russ.)
Kukes VG, Bochkov NP, Sychev DA, Ignat’ev IV. Klinicheskaya farmakogenetika. M.: GEOTAR-MEDIA; 2007. (In Russ.)
Sychev DA. Farmakogeneticheskoe testirovanie: klinicheskaya interpritatsiya rezul’tatov. Rekomendatsii dlya praktikuyushchikh vrachei. M.: Litekh; 2011. (In Russ.)
Abdrashitov RKh, Gil’deeva GN, Ramenskaya GV, Smirnov VV. Review of existing methodologies to assess the activity of CYP2D6 using exogenous and endogenous markers. Farmakokinetika i farmakodinamika. 2015;1:4-11. (In Russ.)
Gaedigk A, Bradford LD, Marcucci KA, Leeder JS. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clinical Pharmacology & Therapeutics. 2002;72:1:76-89. https://doi.org/10.1067/mcp.2002.125783
Siest G, Jeannesson E, Berrahmoune H, Maumus S, Marteau JB, Mohr S, Visvikis S. Pharmacogenomics and drug response in cardiovascular disorders. Pharmacogenomics. 2004;5:779-802. https://doi.org/10.1016/s0003-4509(07)90037-1
Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmöller J, Frötschl R, Köpke K, Gerloff T, Chernov JN, Roots I. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. European Journal of Clinical Pharmacology. 2003;59(4):303-312. https://doi.org/10.1007/s00228-003-0606-2
Sheldon HP, et al. Cytochrome P450 2D6 Phenoconversion Is Common in Patients Being Treated for Depression: Implications for Personalized Medicine. The Journal of Clinical Psychiatry. 2013;74(6):614-621. https://doi.org/10.4088/jcp.12m07807
Nieminen T, Lehtimaki T, Maenpaa J, Ropo A, Uusitalo H, Kähönen M. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scandinavian Journal of Clinical and Laboratory Investigation. 2007;67:237-245. https://doi.org/10.1080/00365510601034736
Egorov EA. Undesirable effects of hypotensive treatment. RMJ. Klinicheskaya oftal’mologiya. 2007;8(4):144-147. (In Russ.)
Zimmerman FH, Cameron A, Fisher LD, Ng G. Myocardial infarction in young adults: angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Study Registry). Journal of the American College of Cardiology. 1995;26(3):654-661. https://doi.org/10.1016/0735-1097(95)00254-2
Maskens RP, Wolfs RC, Witteman JC, Hofman A, de Jong PT, Stricker BH, Jansonius NM. Topical beta-blockers and mortality. Ophthalmology. 2008;115(11):2037-2043. https://doi.org/10.1016/j.ophtha.2008.07.004
Higginbotham EJ, Lee DA. Clinical Guide to Glaucoma management. Butterwort & Heinemann Elsevier Inc. 2004;7:107-122.
Yarangymeli A, Kural G. Are there any benefits of Betoptic®S (betaxolol HCl ophthalmic suspension) over other β-blockers in the treatment of glaucoma? Expert Opinion on Pharmacotherapy. 2004;5(5):1071-1081. https://doi.org/10.1517/14656566.5.5.1071
Egorov EA i dr. Oftal’mofarmakologiya. M.: Geotar-Med; 2004. (In Russ.).
Sychjov DA, Moshetova LK. Clinical and pharmacological aspects of combined pathology: cardiovascular diseases and glaucoma. Natsional’nyi zhurnal glaukoma. 2014;2(13):99-104. (In Russ.)
Alvan G, von Bahr C, Seidemann P, Sjöqvist F. High plasma concentrations of beta- receptor blocking drugs and deficient debrisoquine hydroxylation. Lancet. 1982;319:333. https://doi.org/10.1016/s0140-6736(82)91583-5
Lewis RV, Lennard MS, Jackson PR, et al. Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. British Journal of Clinical Pharmacology. 1985;19:329-333. https://doi.org/10.1111/j.1365-2125.1985.tb02651.x
McGourty JC, Silas JH, Fleming JJ. Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin. Clinical Pharmacology and Therapeutics. 1985;38:409-413. https://doi.org/10.1038/clpt.1985.195
Edeki TI, He H, Wood AJ. Pharmacogenetic explanation for excessive beta- blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction. JAMA. 1995;274:1611-1613. https://doi.org/10.1001/jama.1995.03530200047035
Yang Y, Wu K, Yuan H, Yu M. Cytochrome oxidase 2D6 gene polymorphism in primary open — angle glaucoma with various effects to ophthalmic timolol. Ocular Pharmacology and Therapeutics. 2009;25:163-171. https://doi.org/10.1089/jop.2008.0028
Yuan H, Yu M, Yang Y, Wu K, Lin X, Li J. Association of CYP2D6 Single-Nucleotide Polymorphism with Response to Ophthalmic Timolol in Primary Open-Angle Glaucoma- a pilot study. Journal of Ocular Pharmacology and Therapeutics. 2010;26(5):497-501. https://doi.org/10.1089/jop.2010.001
Walckies D, Van der Heyden J, Tafforeau J. Factors associated with excessive polypharmacy in older people. Archives of Public Health. 2015;73:50. https://doi.org/10.1186/s13690-015-0095-7
Huber M, Kölzsch M, Stahlmann R. Ophthalmic drugs as part of polypharmacy in nursing home residents with glaucoma. Drugs Aging. 2013;30:31-38. https://doi.org/10.1007/s40266-012-0036-x
Goldberg I, Adena MA. Co-prescribing of topical and systemic beta-blockers in patients with glaucoma: a quality use of medicine issue in Australian practice. Clinical & Experimental Ophthalmology. 2007;35:700-705. https://doi.org/10.1111/j.1442-9071.2007.01573.x
Brauner SC, Chen TC, Hutchinson BT. The course of glaucoma during pregnancy: a retrospective case series. Archives of Ophthalmology. 2006;124:1089-1094. https://doi.org/10.1001/archopht.124.8.1089
Mendez-Hernandez C, Garcia-Feijoo J, Saenz-Frances F, et al. Topical intraocular pressure therapy effects on pregnancy. Clinical Ophthalmology. 2012;6:1629-1632. https://doi.org/10.2147/opth.s36712
Wagenvoort AM, van Vugt JM, Sobotka M, van Geijn HP. Topical timolol therapy in pregnancy: is it safe for the fetus? Teratology. 1998;58:258-262. https://doi.org/10.1002/(sici)1096-9926(199812)58:6%3C258::aidtera7%3E3.0.co;2-b
Weibel L, Barysch M, Scheer HS, et al. Topical timolol: Evidence for efficacy and degree of systemic absorption. Pediatric Dermatology. 2016;33:184-190. https://doi.org/10.1111/pde.12767
Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metabolism Reviews. 2009;41:67-76. https://doi.org/10.1080/03602530902722679
Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Archives of Ophthalmology. 2010;4:1-9. https://doi.org/10.1001/archophthalmol.2009.384